Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM.
Juvekar A, et al. Among authors: rajendran a.
Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22.
Cancer Discov. 2012.
PMID: 22915751
Free PMC article.